Skip to Main Content

Author Details

Stephen B Keysar
University of Colorado Denver
2006
35
19
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37389416The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.J Natl Cancer Inst2023
35417043Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.Mol Carcinog2022
33087417Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft.Mol Cancer Res2021
34546978Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.JCI Insight2021
32816856Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells.Cancer Res2020
31911553Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma.Cancer Res2020
30575147Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.Mol Carcinog2019
31586893Leading edge or tumor core: Intratumor cancer stem cell niches in oral cavity squamous cell carcinoma and their association with stem cell function.Oral Oncol2019
31417185MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.Oncogene2019
30378175Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions.Mol Carcinog2019
29555661Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression.Clin Cancer Res2018
30129680Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.Mol Carcinog2018
27649287Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.Mol Carcinog2017
28315646Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate <i>Corynebacterium bovis</i>.J Am Assoc Lab Anim Sci2017
28428274EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.Cancer Res2017
25893296XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer.Oncogene2016
27634934Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.J Natl Cancer Inst2016
27941840Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.Sci Rep2016
26705064A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.Oral Oncol2016
26152787A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.Int J Cancer2016
25946135An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.PLoS One2015
26697402DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation.Front Oncol2015
26216294An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.Cancer Discov2015
24493827Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.Clin Cancer Res2014
25297633Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.Cancer Res2014
23576557Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.Cancer Res2013
23873848The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.Mol Cancer Ther2013
23999427Epithelial stem cell mutations that promote squamous cell carcinoma metastasis.J Clin Invest2013
23607916A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.Mol Oncol2013
20041756Hypoxia/reoxygenation-induced mutations in mammalian cells detected by the flow cytometry mutation assay and characterized by mutant spectrum.Radiat Res2010
20716638More than markers: biological significance of cancer stem cell-defining molecules.Mol Cancer Ther2010
19291804Kinetics of CHO A L mutant expression after treatment with gamma radiation, EMS, and asbestos.Cytometry A2009
19463836EMS mutant spectra generated by multi-parameter flow cytometry.Mutat Res2009
17512559Mutant spectra of irradiated CHO AL cells determined with multiple markers analyzed by flow cytometry.Mutat Res2007
17045307Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay.Mutat Res2006
  • 1 - 35 of 35

Recommended Authors

Moores Cancer Center, University of California
Career Start Year 2015
Number of shared co-authors 0
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2014
Number of shared co-authors 0
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 7
Osaka University Graduate School of Medicine
Career Start Year 2012
Number of shared co-authors 1
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Career Start Year 2012
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Moores Cancer Center, University of California San Diego
Career Start Year 2008
Number of shared co-authors 9
Cumming School of Medicine, University of Calgary
Career Start Year 2008
Number of shared co-authors 0
Cancer Biology Research Center
Career Start Year 2008
Number of shared co-authors 1
Princess Margaret Cancer Research Centre
Career Start Year 2007
Number of shared co-authors 0
George Washington University
Career Start Year 2007
Number of shared co-authors 12
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 2
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Center for Cancer Research, University of Tennessee Health Science Center
Career Start Year 1999
Number of shared co-authors 3
University of Chicago Medicine
Career Start Year 1999
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 0
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 5
Baylor College of Medicine
Career Start Year 1995
Number of shared co-authors 2
University of Toronto
Career Start Year 1991
Number of shared co-authors 0
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 5
Brigham and Women's Hospital
Career Start Year 1988
Number of shared co-authors 2
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 2
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 0
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 1
Vrije Universiteit Amsterdam
Career Start Year 1986
Number of shared co-authors 1
University of North Carolina at Chapel Hill
Career Start Year 1986
Number of shared co-authors 4
National Institute of Deafness and Other Communication Disorders
Career Start Year 1984
Number of shared co-authors 1
Kresge Hearing Research Institute, University of Michigan ann arbor
Career Start Year 1976
Number of shared co-authors 1

Collaborators

University of Colorado School of Medicine
Co-authored papers 29
Huntsman Cancer Institute, The University of Utah
Co-authored papers 11
University of Colorado Anschutz Medical Campus
Co-authored papers 6
Co-authored papers 5
University of Colorado Anschutz Medical Campus
Co-authored papers 4
University of Colorado School of Medicine
Co-authored papers 3
National Centre for Asbestos Related Diseases, University of Western Australia
Co-authored papers 2
Universite de Sherbrooke
Co-authored papers 2
University of Colorado Denver at Anschutz Medical Campus
Co-authored papers 2
Zai Lab (US) LLC
Co-authored papers 1
The University of New Mexico School of Medicine
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
Cornell University
Co-authored papers 1
Co-authored papers 1
University of California san francisco
Co-authored papers 1
University of California san francisco
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
Co-authored papers 1
University of California san francisco
Co-authored papers 1
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
University of Colorado Anschutz Medical Campus
Co-authored papers 1
University of Colorado Anschutz Medical Campus
Co-authored papers 1
University of California San Francisco.
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
University of California
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
University of California san francisco
Co-authored papers 1
University of Texas MD Anderson Cancer Center
Co-authored papers 1
Co-authored papers 1